Takeda has also ended the collaboration agreement with Cell Genesys for the development and commercialization of the product.
Under the terms of the agreement, Takeda will return all commercial rights to Gvax immunotherapy for prostate cancer to Cell Genesys and make certain wind-down payments to Cell Genesys in connection with the phasing out of the remaining clinical development activities.